Sichuan Biokin Stock Hits Day Low Amid Price Pressure, Drops to CNY 245.87

Sichuan Biokin Pharmaceutical Co., Ltd. experienced a notable decline today, with the stock dropping by 3.01% to touch an intraday low of CNY 245.87. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 1.26% during the same period. Over the past week, Sichuan Biokin has seen a significant decrease of 14.59%, while its monthly performance reflects an 8.59% decline. Year-to-date, the stock has faced a challenging environment, with a drop of 23.45%, compared to a modest gain of 2.85% for the Shanghai Composite. However, on a longer-term basis, the stock has shown resilience, with a remarkable increase of 256.38% over the past three years. Financial metrics indicate that the company has faced difficulties, reporting negative net sales growth of 63.52% and a net profit decline of 112.34% over the last nine months. The operating cash flow has also reached a low of CNY -2,331.46 million. As a large-cap player in the pharmaceuticals and biotechnology sector, Sichuan Biokin's current market cap stands at CNY 29,530 million.